ES2629317T3 - Tratamiento de tumores cerebrales sólidos con un derivado de rapamicina - Google Patents

Tratamiento de tumores cerebrales sólidos con un derivado de rapamicina Download PDF

Info

Publication number
ES2629317T3
ES2629317T3 ES14164565.5T ES14164565T ES2629317T3 ES 2629317 T3 ES2629317 T3 ES 2629317T3 ES 14164565 T ES14164565 T ES 14164565T ES 2629317 T3 ES2629317 T3 ES 2629317T3
Authority
ES
Spain
Prior art keywords
combination
treatment
administration
brain tumors
rapamycin derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES14164565.5T
Other languages
English (en)
Spanish (es)
Inventor
Heidi Lane
Terence O'reilly
Jeanette Marjorie Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26245731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2629317(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0104072A external-priority patent/GB0104072D0/en
Priority claimed from GB0124957A external-priority patent/GB0124957D0/en
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2629317T3 publication Critical patent/ES2629317T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
ES14164565.5T 2001-02-19 2002-02-18 Tratamiento de tumores cerebrales sólidos con un derivado de rapamicina Expired - Lifetime ES2629317T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0104072 2001-02-19
GB0104072A GB0104072D0 (en) 2001-02-19 2001-02-19 Organic compounds
GB0124957A GB0124957D0 (en) 2001-10-17 2001-10-17 Organic compounds
GB0124957 2001-10-17

Publications (1)

Publication Number Publication Date
ES2629317T3 true ES2629317T3 (es) 2017-08-08

Family

ID=26245731

Family Applications (8)

Application Number Title Priority Date Filing Date
ES14164565.5T Expired - Lifetime ES2629317T3 (es) 2001-02-19 2002-02-18 Tratamiento de tumores cerebrales sólidos con un derivado de rapamicina
ES18155722T Expired - Lifetime ES2921798T3 (es) 2001-02-19 2002-02-18 Derivado de rapamicina para el tratamiento de tumores sólidos
ES14164259.5T Expired - Lifetime ES2640787T3 (es) 2001-02-19 2002-02-18 Combinación de un derivado de rapamicina y letrozol para tratar el cáncer de mama
ES10174983.6T Expired - Lifetime ES2543383T3 (es) 2001-02-19 2002-02-18 Tratamiento de tumores de mama con un derivado de rapamicina en combinación con exemestano
ES18155724T Expired - Lifetime ES2744377T3 (es) 2001-02-19 2002-02-18 Derivado de rapamicina para tratar cáncer de páncreas
ES16186041T Expired - Lifetime ES2705016T3 (es) 2001-02-19 2002-02-18 Derivado de rapamicina para el tratamiento de cáncer de pulmón
ES10174985.1T Expired - Lifetime ES2600304T3 (es) 2001-02-19 2002-02-18 Tratamiento de tumores sólidos de riñón con un derivado de rapamicina
ES18155644T Expired - Lifetime ES2728739T3 (es) 2001-02-19 2002-02-18 Derivado de rapamicina para el tratamiento de un tumor sólido asociado con angiogénesis desregulada

Family Applications After (7)

Application Number Title Priority Date Filing Date
ES18155722T Expired - Lifetime ES2921798T3 (es) 2001-02-19 2002-02-18 Derivado de rapamicina para el tratamiento de tumores sólidos
ES14164259.5T Expired - Lifetime ES2640787T3 (es) 2001-02-19 2002-02-18 Combinación de un derivado de rapamicina y letrozol para tratar el cáncer de mama
ES10174983.6T Expired - Lifetime ES2543383T3 (es) 2001-02-19 2002-02-18 Tratamiento de tumores de mama con un derivado de rapamicina en combinación con exemestano
ES18155724T Expired - Lifetime ES2744377T3 (es) 2001-02-19 2002-02-18 Derivado de rapamicina para tratar cáncer de páncreas
ES16186041T Expired - Lifetime ES2705016T3 (es) 2001-02-19 2002-02-18 Derivado de rapamicina para el tratamiento de cáncer de pulmón
ES10174985.1T Expired - Lifetime ES2600304T3 (es) 2001-02-19 2002-02-18 Tratamiento de tumores sólidos de riñón con un derivado de rapamicina
ES18155644T Expired - Lifetime ES2728739T3 (es) 2001-02-19 2002-02-18 Derivado de rapamicina para el tratamiento de un tumor sólido asociado con angiogénesis desregulada

Country Status (27)

Country Link
US (10) US8410131B2 (enExample)
EP (11) EP3345602B1 (enExample)
JP (14) JP2004525899A (enExample)
KR (3) KR100695846B1 (enExample)
CN (5) CN1551767A (enExample)
AU (1) AU2002250968C1 (enExample)
BR (1) BR0207378A (enExample)
CA (3) CA2994779C (enExample)
CY (11) CY1116616T1 (enExample)
CZ (5) CZ309178B6 (enExample)
DK (6) DK2762140T3 (enExample)
ES (8) ES2629317T3 (enExample)
HK (2) HK1250336B (enExample)
HU (1) HUP0303271A3 (enExample)
IL (13) IL157425A0 (enExample)
LT (9) LT2269604T (enExample)
LU (3) LU92880I2 (enExample)
MX (3) MX368013B (enExample)
NO (14) NO333105B1 (enExample)
NZ (1) NZ527692A (enExample)
PL (5) PL231418B1 (enExample)
PT (7) PT2762140T (enExample)
RU (8) RU2322981C2 (enExample)
SI (6) SI3342411T1 (enExample)
SK (5) SK288834B6 (enExample)
TW (2) TW200626151A (enExample)
WO (1) WO2002066019A2 (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1158985B1 (en) 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
CZ309178B6 (cs) * 2001-02-19 2022-04-20 Novartis Pharma Ag 40-O-(2-hydroxyethyl)rapamycin pro použití při léčení
PL367267A1 (en) * 2001-06-01 2005-02-21 Wyeth Antineoplastic combinations
ES2425739T3 (es) 2002-02-11 2013-10-17 Bayer Healthcare Llc Sorafenib-tosilato para el tratamiento de enfermedades caracterizadas por angiogénesis anormal
PT1545553E (pt) 2002-07-30 2011-09-12 Aeterna Zentaris Gmbh Utilização de alquilfosfocolinas em combinação com medicamentos antitumorais
US8383605B2 (en) 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
US7846141B2 (en) 2002-09-03 2010-12-07 Bluesky Medical Group Incorporated Reduced pressure treatment system
EP1553939A1 (en) * 2002-10-11 2005-07-20 Dana-Farber Cancer Institute, Inc. Epothilone derivatives for the treatment of multiple myeloma
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
ES2305808T3 (es) 2003-05-20 2008-11-01 Bayer Healthcare Llc Diarilureas con actividad inhibidora de quinasas.
BRPI0412219B8 (pt) 2003-07-23 2021-07-27 Bayer Healthcare Llc compostos ômega-carboxi aril difenil uréia fluoro substituídos e composições farmacêuticas compreendendo os referidos compostos
CN102144961A (zh) 2003-09-18 2011-08-10 参天制药株式会社 经巩膜递送
KR101382077B1 (ko) * 2004-02-23 2014-04-10 노파르티스 아게 Mtor 억제제와 세포독성제의 복합 치료에 대한 바이오마커로서의 p53 야생형
GB0406446D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
NZ549552A (en) * 2004-03-23 2009-12-24 Astrazeneca Ab Combination therapy involving 4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline (AZD2171) and a platinum anti-tumour agent
CN104147005B (zh) 2005-02-09 2018-07-03 参天制药株式会社 用于治疗疾病或病症的液体制剂
CN102357104B (zh) * 2005-03-07 2016-01-27 罗巴斯研究机构 粘液瘤病毒与雷帕霉素的组合在治疗性处理中的应用
GB0504995D0 (en) * 2005-03-11 2005-04-20 Biotica Tech Ltd Use of a compound
GB0504994D0 (en) * 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
US20100061994A1 (en) * 2005-03-11 2010-03-11 Rose Mary Sheridan Medical uses of 39-desmethoxyrapamycin and analogues thereof
GB0507918D0 (en) 2005-04-19 2005-05-25 Novartis Ag Organic compounds
US20080200486A1 (en) * 2005-07-20 2008-08-21 Heidi Lane Combination Of Organic Compounds
EP2662082A1 (en) 2005-11-14 2013-11-13 Ariad Pharmaceuticals, Incorporated Administration of mTOR inhibitors
CA2629245C (en) * 2005-11-21 2016-07-12 Novartis Ag Neuroendocrine tumor treatment
AU2007211613C1 (en) 2006-02-02 2018-01-04 Novartis Ag Tuberous Sclerosis treatment
GB0602123D0 (en) * 2006-02-02 2006-03-15 Novartis Ag Organic compounds
JP5528708B2 (ja) 2006-02-09 2014-06-25 参天製薬株式会社 安定な製剤ならびにそれらを調製および使用する方法
JP5506378B2 (ja) 2006-03-23 2014-05-28 参天製薬株式会社 血管透過性に関連する疾患または病気のための製剤および方法
EP2004163B1 (en) * 2006-04-05 2014-09-17 Novartis Pharma AG Combination of everolimus and vinorelbine
CA2661024A1 (en) * 2006-08-28 2008-03-06 The Regents Of The University Of California Small molecule potentiator of hormonal therapy for breast cancer
US9820888B2 (en) 2006-09-26 2017-11-21 Smith & Nephew, Inc. Wound dressing
RU2483714C2 (ru) * 2007-03-07 2013-06-10 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи. Наночастица, содержащая рапамицин и альбумин, в качестве противоракового агента
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
CN101292980B (zh) * 2007-04-28 2010-11-10 上海交通大学医学院附属仁济医院 一种含有雷帕霉素的用于治疗大肠癌的药物组合物
ES2706023T3 (es) * 2007-08-16 2019-03-27 Biocompatibles Uk Ltd Administración de combinaciones de fármacos
US20090149511A1 (en) * 2007-10-30 2009-06-11 Syndax Pharmaceuticals, Inc. Administration of an Inhibitor of HDAC and an mTOR Inhibitor
US8298200B2 (en) 2009-06-01 2012-10-30 Tyco Healthcare Group Lp System for providing continual drainage in negative pressure wound therapy
WO2009126965A2 (en) * 2008-04-11 2009-10-15 The Regents Of The University Of Colorado Compositions, methods and uses for modulations of brca1
AU2009279806B2 (en) * 2008-08-04 2015-04-30 Five Prime Therapeutics, Inc. FGFR extracellular domain acidic region muteins
GB0902368D0 (en) 2009-02-13 2009-04-01 Smith & Nephew Wound packing
GB0922332D0 (en) 2009-12-22 2010-02-03 Isis Innovation Method of treatment and screening method
US8791315B2 (en) 2010-02-26 2014-07-29 Smith & Nephew, Inc. Systems and methods for using negative pressure wound therapy to manage open abdominal wounds
CA2794513A1 (en) 2010-03-31 2011-10-06 Aeterna Zentaris Gmbh Perifosine and capecitabine as a combined treatment for cancer
MY162825A (en) 2010-08-20 2017-07-31 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
UY34487A (es) * 2011-12-05 2013-07-31 Novartis Ag Anticuerpos para receptor de factor de crecimiento epidérmico 3(her3)
EP3354293B1 (en) 2012-05-23 2019-12-11 Smith & Nephew plc Apparatuses for negative pressure wound therapy
EP2879636B1 (en) 2012-08-01 2017-03-22 Smith & Nephew PLC Wound dressing
CA2880148C (en) 2012-08-01 2021-07-20 Smith & Nephew Plc Wound dressing and method of treatment
EP2968648B1 (en) 2013-03-15 2020-12-23 Smith & Nephew plc Wound dressing and method of treatment
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
WO2016066608A1 (en) 2014-10-28 2016-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary cell senescence and peripheral aging
JP6623745B2 (ja) * 2015-06-29 2019-12-25 富士通株式会社 電子回路及び発振器の制御方法
EP3277842B9 (en) * 2015-08-17 2020-01-15 Kura Oncology, Inc. Methods of treating cancer patients with farnesyl transferase inhibitors
WO2017160895A1 (en) * 2016-03-15 2017-09-21 Tyme, Inc. Pharmaceutical compositions for the treatment of cancer
US20200081010A1 (en) 2016-12-02 2020-03-12 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for diagnosing renal cell carcinoma
EP4046989A1 (en) 2017-01-09 2022-08-24 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
WO2019002085A1 (en) 2017-06-30 2019-01-03 Smith & Nephew Plc NEGATIVE PRESSURE WOUND TREATMENT APPARATUS
AR112834A1 (es) 2017-09-26 2019-12-18 Novartis Ag Derivados de rapamicina
WO2019089556A1 (en) * 2017-10-31 2019-05-09 Steve Gorlin Combinations of chemotherapeutic agents and antimicrobial particles and uses thereof
EP3737376B1 (en) 2018-01-09 2024-04-17 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human diseases
SG11202010560QA (en) 2018-05-01 2020-11-27 Revolution Medicines Inc C26-linked rapamycin analogs as mtor inhibitors
FI3788049T3 (fi) 2018-05-01 2023-05-30 Revolution Medicines Inc C40-, c28- ja c-32-liittyneitä rapamysiinianalogeja mtor-estäjinä
CN108825638A (zh) * 2018-08-01 2018-11-16 安徽送变电工程有限公司 一种应用于螺纹工件的防盗装置
HRP20250197T1 (hr) 2018-12-18 2025-04-11 Novartis Ag Derivati rapamicina
GB201905780D0 (en) 2019-04-25 2019-06-05 La Thangue Nicholas Cancer therapy
CN114173578A (zh) 2019-05-14 2022-03-11 迪美公司 用于治疗癌症的组合物和方法
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
KR20230053539A (ko) 2021-10-14 2023-04-21 (주)파로스아이바이오 2,3,5-치환된 싸이오펜 화합물을 포함하는 병용 투여용 조성물
AU2023275778A1 (en) 2022-05-25 2024-12-12 Revolution Medicines, Inc. Methods of treating cancer with an mtor inhibitor

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US876165A (en) 1904-05-11 1908-01-07 George K Woodworth Wireless telegraph transmitting system.
GB104072A (en) 1916-04-14 1917-02-22 William Henry Nosworthy Apparatus for Lighting Fires or Heating or other purposes.
GB124957A (en) 1918-06-04 1919-04-10 Frederick William Miller Improvement in Glass Moulding.
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
BE877700A (fr) * 1978-11-03 1980-01-14 Ayerst Mckenna & Harrison Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US4885171A (en) * 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
LU88769I2 (fr) 1982-07-23 1996-11-05 Zeneca Ltd Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R))
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
GB8517360D0 (en) 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
US5194447A (en) * 1992-02-18 1993-03-16 American Home Products Corporation Sulfonylcarbamates of rapamycin
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
JP3140228B2 (ja) * 1992-02-17 2001-03-05 ファイザー製薬株式会社 新規な大環状ラクトンおよびその生産菌
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (enExample) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5256790A (en) * 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
WO1994009019A1 (en) 1992-10-14 1994-04-28 Unichema Chemie B.V. Process for the preparation of alkylglycosides
JP3398382B2 (ja) 1992-10-28 2003-04-21 ジェネンテク，インコーポレイテッド 血管内皮細胞増殖因子アンタゴニスト
US5258389A (en) * 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
GB2273704B (en) * 1992-12-16 1997-01-22 Orion Yhtymae Oy Triazolyl diaryl selective aromatase inhibiting compounds
DE4301781C2 (de) 1993-01-23 1995-07-20 Lohmann Therapie Syst Lts Nitroglycerinhaltiges Pflaster, Verfahren zu seiner Herstellung und Verwendung
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
US5387680A (en) * 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
EP0729471A1 (en) 1993-11-19 1996-09-04 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
GB9325400D0 (en) 1993-12-11 1994-02-16 Sarll David P G Temperature recorder
CN1046944C (zh) 1993-12-17 1999-12-01 山道士有限公司 雷怕霉素类衍生物
AU2356195A (en) * 1994-04-14 1995-11-10 Sepracor, Inc. Treating estrogen-dependent diseases with (-)-fadrozole
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
GB9417873D0 (en) 1994-09-06 1994-10-26 Sandoz Ltd Organic compounds
IL129547A (en) 1994-10-26 2001-01-11 Novartis Ag Pharmaceutical compositions comprising a macrolide and an acid
EP0817775B1 (en) 1995-03-30 2001-09-12 Pfizer Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5985890A (en) * 1995-06-09 1999-11-16 Novartis Ag Rapamycin derivatives
HUP9900330A3 (en) 1995-07-06 2001-08-28 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
US5567831A (en) * 1995-08-16 1996-10-22 Duguesne University Of The Holy Ghost Non-steroidal sulfatase inhibitor compounds and their method of use
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
DE19549852B4 (de) * 1995-11-29 2009-06-04 Novartis Ag Cyclosporin enthaltende Präparate
GB9601120D0 (en) 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
CN1145614C (zh) 1996-04-12 2004-04-14 沃尼尔·朗伯公司 酪氨酸激酶的不可逆抑制剂，其制药用途及药物组合物
EP0896544B1 (en) * 1996-06-11 2003-02-26 Novartis AG Combination of a somatostatin analogue and a rapamycin
CA2258548C (en) 1996-06-24 2005-07-26 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
US6492330B1 (en) * 1996-08-16 2002-12-10 National Institute Of Immunology Antiangiogenic drugs
US5922730A (en) 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
WO1998009970A2 (en) 1996-09-09 1998-03-12 American Home Products Corporation Alkylated rapamycin derivatives
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
AU4342997A (en) 1996-09-13 1998-04-02 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders
GB9619631D0 (en) 1996-09-20 1996-11-06 British Biotech Pharm Combination therapy
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US5985325A (en) 1997-06-13 1999-11-16 American Home Products Corporation Rapamycin formulations for oral administration
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US6015815A (en) * 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6152347A (en) 1998-01-30 2000-11-28 Acco Brands, Inc. Vertical Stapler
ID27825A (id) † 1998-03-26 2001-04-26 Fujisawa Pharmaceutical Co Sediaan lepas lambat
US8029561B1 (en) 2000-05-12 2011-10-04 Cordis Corporation Drug combination useful for prevention of restenosis
AR018330A1 (es) * 1998-04-27 2001-11-14 Fujisawa Pharmaceutical Co Composiciones farmaceuticas que comprenden macrolidos como agentes activos para la terapia y profilaxis de las enfermedades de la piel
ES2342240T3 (es) 1998-08-11 2010-07-02 Novartis Ag Derivados de isoquinolina con actividad que inhibe la angiogenia.
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
IL143596A0 (en) 1998-12-22 2002-04-21 Genentech Inc Vascular endothelial cell growth factor antagonists and uses thereof
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AU766081B2 (en) 1999-03-30 2003-10-09 Novartis Ag Phthalazine derivatives for treating inflammatory diseases
US6333348B1 (en) * 1999-04-09 2001-12-25 Aventis Pharma S.A. Use of docetaxel for treating cancers
GB9911582D0 (en) 1999-05-18 1999-07-21 Pharmacia & Upjohn Spa Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound
EP1074265A1 (en) 1999-08-03 2001-02-07 Erasmus Universiteit Rotterdam Use of AMH and/or AMH agonists and/or AMH antagonists for long-term control of female fertility
ES2222222T3 (es) 1999-08-18 2005-02-01 Wyeth Esteres hidrosolubles de sdz-rad.
AU2292801A (en) 1999-12-22 2001-07-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Compositions and methods for treatment of breast cancer
WO2001049338A1 (en) 1999-12-30 2001-07-12 Li Wei Pin Controlled delivery of therapeutic agents by insertable medical devices
WO2001051049A1 (en) 2000-01-14 2001-07-19 The Trustees Of The University Of Pennsylvania O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders
US6641811B1 (en) * 2000-02-10 2003-11-04 Cornell Research Foundation, Inc. Use of angiotensin II inhibitors to prevent malignancies associated with immunosuppression
GB0005257D0 (en) 2000-03-03 2000-04-26 Pharmacia & Upjohn Spa Breast cancer hormonal therapy
US6761895B2 (en) 2000-04-17 2004-07-13 Yamanouchi Pharmaceutical Co., Ltd. Drug delivery system for averting pharmacokinetic drug interaction and method thereof
US20020013335A1 (en) 2000-06-16 2002-01-31 American Home Products Corporation Method of treating cardiovascular disease
GB0017635D0 (en) 2000-07-18 2000-09-06 Pharmacia & Upjohn Spa Antitumor combined therapy
PT1318837E (pt) * 2000-08-11 2004-12-31 Wyeth Corp Metodo de tratamenton de carcinoma positivo a receptor de estrogenio
US20050004007A1 (en) * 2000-09-12 2005-01-06 Steven Grant Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitiors and cellular differentiation agents
US6696483B2 (en) * 2000-10-03 2004-02-24 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
AU2002239436B2 (en) 2000-10-31 2007-04-26 Cook Medical Technologies Llc Coated implantable medical device
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
AU2002249826A1 (en) * 2000-12-22 2002-07-30 Avantec Vascular Corporation Delivery of therapeutic capable agents
US20020151508A1 (en) * 2001-02-09 2002-10-17 Schering Corporation Methods for treating proliferative diseases
CZ309178B6 (cs) * 2001-02-19 2022-04-20 Novartis Pharma Ag 40-O-(2-hydroxyethyl)rapamycin pro použití při léčení
DE60228699D1 (de) 2001-04-06 2008-10-16 Wyeth Corp Antineoplastische kombinationspräparate enthaltend cci-779 (rapamycin derivat) zusammen mit gemcitabin oder fluoro-uracil
PL367267A1 (en) * 2001-06-01 2005-02-21 Wyeth Antineoplastic combinations
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
US7488313B2 (en) 2001-11-29 2009-02-10 Boston Scientific Scimed, Inc. Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment
JP2003330447A (ja) 2002-05-15 2003-11-19 Mitsubishi Electric Corp 画像処理装置
CA2629245C (en) 2005-11-21 2016-07-12 Novartis Ag Neuroendocrine tumor treatment
BR112013032887B1 (pt) 2011-07-01 2020-10-06 Coloplast A/S Cateter retal
EP2606816A1 (en) 2011-12-22 2013-06-26 Koninklijke Philips Electronics N.V. A method and system for providing an indication as to the amount of milk remaining in a breast during lactation

Also Published As

Publication number Publication date
EP3342411B1 (en) 2019-08-21
PT3345602T (pt) 2022-07-04
ES2728739T3 (es) 2019-10-28
CY2019030I2 (el) 2020-05-29
CY1119029T1 (el) 2018-01-10
NO336110B1 (no) 2015-05-18
IL220096A0 (en) 2012-07-31
JP2014193901A (ja) 2014-10-09
US8778962B2 (en) 2014-07-15
US20120214774A1 (en) 2012-08-23
HK1250336B (en) 2020-02-07
JP5879391B2 (ja) 2016-03-08
HK1198946A1 (en) 2015-06-19
PT2269604T (pt) 2016-11-04
JP2014208657A (ja) 2014-11-06
MXPA03007418A (es) 2003-11-18
RU2011138835A (ru) 2013-03-27
CN1551767A (zh) 2004-12-01
CY1121314T1 (el) 2020-05-29
KR20070102762A (ko) 2007-10-19
NO335134B1 (no) 2014-09-22
LTPA2019521I1 (lt) 2019-12-10
RU2665138C2 (ru) 2018-08-28
RU2322981C2 (ru) 2008-04-27
IL250676B (en) 2018-06-28
LUC00122I2 (enExample) 2019-12-24
CY2019030I1 (el) 2020-05-29
NO20170803A1 (no) 2003-10-17
IL229156A0 (en) 2013-12-31
CZ2010473A3 (enExample) 2004-01-14
CZ309178B6 (cs) 2022-04-20
SI3143995T1 (sl) 2019-02-28
NO336208B1 (no) 2015-06-15
US20130296359A1 (en) 2013-11-07
LU93320I2 (fr) 2017-01-30
DK2269604T3 (en) 2016-11-14
JP2018100281A (ja) 2018-06-28
JP2020143134A (ja) 2020-09-10
EP3406249A1 (en) 2018-11-28
CY1118316T1 (el) 2017-04-05
JP2017081979A (ja) 2017-05-18
JP2016222705A (ja) 2016-12-28
JP6310970B2 (ja) 2018-04-11
IL157425A0 (en) 2004-03-28
US8436010B2 (en) 2013-05-07
US8877771B2 (en) 2014-11-04
LUC00122I1 (enExample) 2019-06-06
CN104116738A (zh) 2014-10-29
US20130244951A1 (en) 2013-09-19
HK1250019A1 (en) 2018-11-23
BR0207378A (pt) 2004-06-15
PL415000A1 (pl) 2016-02-29
AU2002250968B2 (en) 2006-01-12
CZ303611B6 (cs) 2013-01-09
PL414997A1 (pl) 2016-02-29
EP2269604B1 (en) 2016-07-27
CY1121715T1 (el) 2020-05-29
IL229158A (en) 2017-03-30
ES2921798T3 (es) 2022-08-31
JP6383814B2 (ja) 2018-08-29
HK1146247A1 (en) 2011-05-27
US20040147541A1 (en) 2004-07-29
CA2438504A1 (en) 2002-08-29
DK3351246T3 (da) 2019-06-03
EP2783686A8 (en) 2015-03-04
AU2002250968C1 (en) 2018-01-04
IL229156A (en) 2017-02-28
CN1296043C (zh) 2007-01-24
IL229158A0 (en) 2013-12-31
KR100695846B1 (ko) 2007-03-19
NO20033651D0 (no) 2003-08-18
IL220096A (en) 2015-10-29
JP6904640B2 (ja) 2021-07-21
PL414996A1 (pl) 2016-02-29
CA2860306A1 (en) 2002-08-29
IL229159A0 (en) 2013-12-31
NZ527692A (en) 2005-05-27
IL229157A0 (en) 2013-12-31
ES2600304T3 (es) 2017-02-08
CA2994779A1 (en) 2002-08-29
ES2640787T3 (es) 2017-11-06
IL251270A0 (en) 2017-06-29
MX368013B (es) 2019-09-13
SK288630B6 (sk) 2019-01-08
CZ200591A3 (cs) 2019-01-23
SK288524B6 (sk) 2018-01-04
PL231418B1 (pl) 2019-02-28
CN104083365A (zh) 2014-10-08
EP2783686A1 (en) 2014-10-01
RU2005105664A (ru) 2006-08-10
PT2762140T (pt) 2017-07-04
IL157425A (en) 2013-10-31
CZ2019248A3 (cs) 2004-01-14
IL259724A (en) 2018-08-30
EP2764865A3 (en) 2014-10-01
LT3351246T (lt) 2019-07-10
NO2015010I1 (no) 2015-03-30
SI2269604T1 (sl) 2016-11-30
KR20050095906A (ko) 2005-10-04
HK1250018B (en) 2020-04-17
CY2019043I1 (el) 2020-05-29
CA2438504C (en) 2016-02-16
LT3342411T (lt) 2019-09-25
ES2744377T3 (es) 2020-02-24
CY2015044I2 (el) 2017-03-15
LU92880I2 (fr) 2016-11-17
JP2018168188A (ja) 2018-11-01
PL409579A1 (pl) 2015-03-02
JP5873128B2 (ja) 2016-03-01
RU2013119705A (ru) 2014-11-10
JP2004525899A (ja) 2004-08-26
NO20131546L (no) 2003-10-17
NO333105B1 (no) 2013-03-04
NO20120451L (no) 2003-10-17
LTC2269604I2 (lt) 2020-01-27
CZ307637B6 (cs) 2019-01-23
CY1116616T1 (el) 2017-03-15
HK1197723A1 (en) 2015-02-13
NO336581B1 (no) 2015-09-28
US20130253000A1 (en) 2013-09-26
US8410131B2 (en) 2013-04-02
CY2015044I1 (el) 2017-03-15
US20160303092A1 (en) 2016-10-20
CA2994779C (en) 2020-08-25
RU2659725C2 (ru) 2018-07-03
JP6349474B2 (ja) 2018-06-27
EP2762140B1 (en) 2017-03-22
RU2013143306A (ru) 2015-03-27
ES2705016T3 (es) 2019-03-21
TW200626151A (en) 2006-08-01
SI3351246T1 (sl) 2019-08-30
PT2269603E (pt) 2015-09-09
RU2006140514A (ru) 2008-05-27
KR20040007451A (ko) 2004-01-24
EP2269603B1 (en) 2015-05-20
NO20161348A1 (no) 2016-08-24
NO340553B1 (no) 2017-05-08
JP6333766B2 (ja) 2018-05-30
IL229160A0 (en) 2013-12-31
RU2003127391A (ru) 2005-03-27
SK288546B6 (sk) 2018-03-05
EP1363627A2 (en) 2003-11-26
PT3143995T (pt) 2019-01-17
EP3345602B1 (en) 2022-04-06
US20130287769A1 (en) 2013-10-31
JP2014177469A (ja) 2014-09-25
DK2269603T3 (en) 2015-08-24
NO20150413L (no) 2003-10-17
EP2762140A1 (en) 2014-08-06
EP3345602A1 (en) 2018-07-11
NO334646B1 (no) 2014-05-05
EP3143995B1 (en) 2018-12-05
NO343599B1 (no) 2019-04-08
JP6349476B2 (ja) 2018-06-27
SK10382003A3 (sk) 2004-03-02
JP2015145411A (ja) 2015-08-13
NO20150895L (no) 2003-10-17
RU2018127821A (ru) 2020-01-30
LT2762140T (lt) 2017-06-26
NO339240B1 (no) 2016-11-21
RU2325906C2 (ru) 2008-06-10
TWI334350B (en) 2010-12-11
LT3143995T (lt) 2019-01-25
DK2762140T3 (en) 2017-07-10
PT3342411T (pt) 2019-09-19
NO20150831A1 (no) 2015-06-24
SI2269603T1 (sl) 2015-08-31
EP3351246B8 (en) 2019-09-18
US20140105895A1 (en) 2014-04-17
IL250676A0 (en) 2017-03-30
CY2020005I1 (el) 2020-05-29
US20120283285A1 (en) 2012-11-08
LT2269604T (lt) 2016-11-10
JP5775022B2 (ja) 2015-09-09
SI3342411T1 (sl) 2019-10-30
MX2019010879A (es) 2019-12-16
IL259724B (en) 2021-12-01
LTPA2019511I1 (lt) 2019-06-25
CN104274442A (zh) 2015-01-14
LTPA2016035I1 (lt) 2016-12-27
PL363918A1 (pl) 2004-11-29
NO20131547L (no) 2003-10-17
HUP0303271A3 (en) 2010-09-28
SK902019A3 (enExample) 2004-03-02
US20130059877A1 (en) 2013-03-07
CZ20032209A3 (cs) 2004-01-14
PT3351246T (pt) 2019-06-07
KR100695846B9 (ko) 2021-09-30
JP2018100283A (ja) 2018-06-28
EP3143995B2 (en) 2025-01-15
EP2269603A1 (en) 2011-01-05
NO20131545L (no) 2003-10-17
IL251270B (en) 2018-06-28
SK288545B6 (sk) 2018-03-05
CA2860306C (en) 2018-04-17
JP6349475B2 (ja) 2018-06-27
JP2012184238A (ja) 2012-09-27
SI2762140T1 (sl) 2017-07-31
NO20130045L (no) 2003-10-17
JP2018100282A (ja) 2018-06-28
IL229160B (en) 2018-08-30
JP2007284454A (ja) 2007-11-01
CY2016047I2 (el) 2017-04-05
ES2543383T3 (es) 2015-08-18
IL202155A (en) 2013-04-30
CY2016047I1 (el) 2017-04-05
WO2002066019A3 (en) 2002-10-24
HK1146245A1 (en) 2011-05-27
NO20190290A1 (no) 2003-10-17
EP2783686B1 (en) 2017-06-21
DK3143995T3 (en) 2019-01-28
EP2269604A1 (en) 2011-01-05
IL202155A0 (en) 2010-06-16
NO20033651L (no) 2003-10-17
EP3351246A1 (en) 2018-07-25
EP3351246B1 (en) 2019-05-22
RU2445093C2 (ru) 2012-03-20
DK3342411T3 (da) 2019-09-02
NO20131544L (no) 2003-10-17
EP3342411A1 (en) 2018-07-04
CY1121983T1 (el) 2020-05-29
CZ309247B6 (cs) 2022-06-22
LTPA2020503I1 (lt) 2020-03-10
IL220095A0 (en) 2012-07-31
IL220095A (en) 2017-05-29
EP2764865A2 (en) 2014-08-13
HUP0303271A2 (hu) 2004-01-28
NO336428B1 (no) 2015-08-17
CZ2018211A3 (enExample) 2004-01-14
RU2018121314A (ru) 2019-12-10
RU2483727C1 (ru) 2013-06-10
EP3143995A1 (en) 2017-03-22
CZ307940B6 (cs) 2019-09-04
RU2018121314A3 (enExample) 2021-10-06
CN1679559A (zh) 2005-10-12
SK288834B6 (sk) 2021-03-10
WO2002066019A2 (en) 2002-08-29
NO340924B1 (no) 2017-07-17

Similar Documents

Publication Publication Date Title
ES2629317T3 (es) Tratamiento de tumores cerebrales sólidos con un derivado de rapamicina
US9549922B2 (en) Use of eribulin and lenvatinib as combination therapy for treatment of cancer
KR20180132939A (ko) 암 치료를 위한 조합 요법
JP2017516802A (ja) がんの治療におけるエリブリンの使用
BR112020015520A2 (pt) terapia de combinação para câncer com complexo de anel macrocíclico pentaaza e agente anticâncer à base de platina
ES2698363T3 (es) Composiciones de oxprenolol para tratar el cáncer
CN1429114A (zh) 联合化学疗法
WO2015142867A1 (en) Synergistic enhancement of 5-fluorouracil cytotoxicity by deoxyuridine analogs in cancer cells
AU2014279721A1 (en) Pharmaceutical combinations of a PI3K inhibitor and a microtubule destabilizing agent
RU2007119545A (ru) Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743)
WO2019002542A1 (en) COMBINATION OF AN INHIBITOR OF MPS1 AND A TAXANE COMPOUND, USES THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME
WO2015191576A1 (en) Combination therapy comprising a liposomal prodrug of mitomycin c and radiotherapy
EP4203963A1 (en) Combination therapy of a raf inhibitor and a mek inhibitor for the treatment of sarcoma
US20210308111A1 (en) Clinical Methods And Pharmaceutical Compositions Employing AMPA Receptor Antagonists To Treat Glioblastoma And Other Cancers
ES2275619T3 (es) Quetiapina para el tratamiento de discinesia en pacientes no psicoticos.
JP2019131508A (ja) ペンタアザ大環状環複合体および白金を基にした抗癌剤による組み合わせ癌療法
US20220184034A1 (en) Methods for treating cutaneous metastatic cancers
WO2023009500A1 (en) Pentaaza macrocyclic ring complex for enhanced surgical treatment
KR20240004543A (ko) 혈액암을 치료하는 방법
JP2006518355A (ja) インドロピロロカルバゾール誘導体及び他の抗腫瘍薬を含む併用療法
Daud et al. 494 A phase I trial of SCH900776, a selective inhibitor of checkpoint kinase CHK-1, in combination with Gemcitabine in advanced solid tumors
EA040162B1 (ru) Комбинация mcl-1 ингибитора и таксанового соединения, их применения и фармацевтические композиции
KR20100131457A (ko) 시티딘 유도체 및 카르보플라틴을 함유하는 항종양제
HK1140145B (en) Compositions for contributing to the treatment of cancers